The National Institutes of Health, through its NIH Guide, has recently published the following funding-related policy notices, general notices, notices of changes, notices of special interest NOSI, and funding opportunities.

General Notices

• Notice of Early Expiration of "Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions for Research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)
  National Institute of Allergy and Infectious Diseases

• Notice Announcing the National Institute of Mental Health (NIMH) Expectations for Collection of Common Data Elements
  National Institute of Mental Health

• Guidance for Applicants Preparing Applications for the Fall 2020 Due Dates During the COVID-19 Pandemic
  National Institutes of Health

• Request for Information (RFI): Seeking Stakeholder Input on Scientific Gaps and Research Needs Related to Delivery of Cancer-related Care via Telehealth
  National Cancer Institute

Notice of Changes to Funding Opportunities

• Notice to Extend the Expiration Date for PAR-17-287 "NIA Academic Leadership Career Award (K07)"
  National Institute on Aging

• Notice of NIAMS Participation in PA-20-135, "Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional)"
  National Institute of Arthritis and Musculoskeletal and Skin Diseases

• Notice of Participation of NCCIH in PAR-19-342, "Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Institutionally-Focused Research Education Award to Promote Diversity (UE5 - Clinical Trial Not Allowed)"
  National Center for Complementary and Integrative Health

• Notice of Participation of NCCIH in PAR-19-343, "Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Postdoctoral Career Transition Award to Promote Diversity (K99/R00 - Independent Clinical Trial Not Allowed)"
  National Center for Complementary and Integrative Health

• Notice of Clarification to Key Dates for RFA-CA-20-039 "Emergency Awards: Research Projects in SARS-CoV-2 Serological Sciences (U01 Clinical Trial Optional)"
  National Cancer Institute

• Notice of Changes to the Dates in the Final Receipt, Review, Council, and Award Cycle and to the Expiration Date of PAR-19-101, "Physical Sciences-Oncology Network (PS-ON): Physical Sciences-Oncology Projects (PS-OP) (U01 Clinical Trial Optional)"
  National Cancer Institute

• Notice to Add a Receipt Date to RFA-DA-21-019 Single Cell Opioid Responses in the Context of HIV (SCORCH) Program Expansion: CNS Data Generation for Chronic Opioid, Methamphetamine, and/or Cocaine Exposures (U01 Clinical Trial Not Allowed)
  National Institute on Drug Abuse

• Notice of Change to Application Receipt Dates and Clarification of Eligibility Information for PAR-20-220, Institutional Network Award for Promoting Kidney, Urologic, and Hematologic Research Training (U2C-Clinical Trial Not Allowed)
  National Institute of Diabetes and Digestive and Kidney Diseases

• Notice of Change to Instructions for Human Subjects and Clinical Trial Information in PAR-19-312 Limited Competition: Renewal of Centers of Biomedical Research Excellence (COBRE) (Phase 2) (P20 Clinical Trial Optional)"
  National Institute of General Medical Sciences

• Notice of Change to Instructions for Human Subjects and Clinical Trial Information in PAR-19-313 "Centers of Biomedical Research Excellence (COBRE) Phase 1 (P20 Clinical Trial Optional)
  National Institute of General Medical Sciences

• Notice to Extend Response Date for NOT-GM-20-034: "Request for Information: Soliciting Input on the NIGMS 2021-2025 Strategic Plan Framework"
  National Institute of General Medical Sciences

• Notice of Additional Eligibility Information in PAR-20-100 Genomic Community Resources (U24)
  National Human Genome Research Institute

• Notice of Participation in PA-18-358, "NINDS Exploratory Neuroscience Research Grant (R21- Clinical Trial Optional)"
  National Institute of Mental Health
  National Institute of Neurological Disorders and Stroke

• Notice of New Budget Limitation for PAR-18-657 "Countermeasures Against Chemical Threats (CounterACT) Research Centers of Excellence (U54 Clinical Trial Optional)"
  National Institute of Neurological Disorders and Stroke
  National Eye Institute
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  National Institute on Drug Abuse
  National Institute of Environmental Health Sciences

• Notice of Change to Key Dates for PAR-18-657 "Countermeasures Against Chemical Threats (CounterACT) Research Centers of Excellence (U54 Clinical Trial Optional)".
• Notice of Change to Key Dates for PAR-19-039 "Countermeasures Against Chemical Threats (CounterACT): Identification of Therapeutic Lead Compounds (U01 Clinical Trial Not Allowed)"
• Notice of Change to Key Dates for PAR-19-040 "Countermeasures Against Chemical Threats (CounterACT): Optimization of Therapeutic Lead Compounds (U01 Clinical Trial Optional)"
  National Institute of Neurological Disorders and Stroke
  National Eye Institute
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  National Institute on Drug Abuse
  National Institute of Environmental Health Sciences

• Notice of Clarification to Application Types Allowed PAR-20-111 "Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)"
  National Institute of Neurological Disorders and Stroke

• Notice of Change to Key Dates for RFA-NS-20-030 "Research Program Award (R35 Clinical Trial Optional)"
  National Institute of Neurological Disorders and Stroke

Notices of Intent to Publish

• Notice of Intent to Publish a Funding Opportunity Announcement for ALACRITY Centers for Practice-Based Effectiveness and Services Research with Near-Term Impact (P50 Clinical Trial Optional)
  National Institute of Mental Health

• Notice of Intent to Publish Funding Opportunity Announcements for the RADx-rad Initiative
  National Institutes of Health

Notices of Special Interest

• Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions for Select Research Activities related to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)
  National Institute of Allergy and Infectious Diseases

• Notice of Special Interest (NOSI): National Cancer Institute (NCI) Emergency Administrative Supplements for Research and Training Continuity of Postdoctoral Fellows during Coronavirus Disease 2019 (COVID-19)
  National Cancer Institute

Funding Opportunities

• Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship to Promote Diversity in Health-Related Research (Parent F31-Diversity)
  National Institutes of Health
  National Center for Complementary and Integrative Health
  National Cancer Institute
  National Eye Institute
  National Human Genome Research Institute
  National Heart, Lung, and Blood Institute
  National Institute on Aging
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Allergy and Infectious Diseases
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  National Institute of Biomedical Imaging and Bioengineering
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute on Drug Abuse
  National Institute on Deafness and Other Communication Disorders
  National Institute of Dental and Craniofacial Research
  National Institute of Diabetes and Digestive and Kidney Diseases
  National Institute of Environmental Health Sciences
  National Institute of General Medical Sciences
  National Institute of Mental Health
  National Institute on Minority Health and Health Disparities
  National Institute of Neurological Disorders and Stroke
  National Institute of Nursing Research
  National Library of Medicine
  Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs
   
• SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance (SB1, Clinical Trial Not Allowed)
  National Institutes of Health
  National Center for Advancing Translational Sciences
  National Center for Complementary and Integrative Health
  National Cancer Institute
  National Eye Institute
  National Human Genome Research Institute
  National Heart, Lung, and Blood Institute
  National Institute on Aging
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  National Institute of Biomedical Imaging and Bioengineering
  National Institute on Deafness and Other Communication Disorders
  National Institute of Dental and Craniofacial Research
  National Institute of Diabetes and Digestive and Kidney Diseases
  National Institute of Environmental Health Sciences
  National Institute of General Medical Sciences
  National Institute of Mental Health
  National Library of Medicine
   
• SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late Stage Development (SB1, Clinical Trial Not Allowed)
  National Institutes of Health
  National Eye Institute
  National Heart, Lung, and Blood Institute
  National Institute on Aging
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Allergy and Infectious Diseases
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute on Deafness and Other Communication Disorders
  National Institute of Dental and Craniofacial Research
  National Institute of Diabetes and Digestive and Kidney Diseases
  National Institute of General Medical Sciences
  National Institute of Mental Health
  National Institute of Neurological Disorders and Stroke.
• SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late Stage Development (SB1 Clinical Trial Required)
  (PAR-20-130)
  National Institutes of Health
  National Eye Institute
  National Heart, Lung, and Blood Institute
  National Institute on Aging
  National Institute on Alcohol Abuse and Alcoholism
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute on Deafness and Other Communication Disorders
  National Institute of Mental Health
  National Institute of Neurological Disorders and Stroke
   
• Countermeasures Against Chemical Threats (CounterACT) Exploratory/Developmental Projects (R21 Clinical Trial Not Allowed)
  National Institute of Neurological Disorders and Stroke
  National Eye Institute
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  National Institute on Drug Abuse
  National Institute of Environmental Health Sciences
   
• Tobacco Use and HIV in Low and Middle-Income Countries (U01 Clinical Trial Optional)
  National Cancer Institute
   
• Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Clinical Centers (U01 Clinical Trial Required)
• Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
  National Institute of Diabetes and Digestive and Kidney Diseases
   
• Mechanistic Studies of the Interaction between SARS-CoV-2/COVID-19 and Diseases and Organ Systems of Interest to NIDDK (R01 Clinical Trial Optional)
  National Institute of Diabetes and Digestive and Kidney Diseases
   
• Development of Standard Core Clinical Outcomes Assessments (COAs) and Endpoints (UG3/UH3 Clinical Trial Optional)
  Food and Drug Administration

Members of the University of Iowa community may direct questions to the UI Division of Sponsored Programs at dsp@uiowa.edu  or 335-2123, or email Carrie Damon at carolyn-damon@uiowa.edu  or Dave Myers at dave-myers@uiowa.edu  or Lynn Hudachek at lynn-hudachek @uiowa.edu